TransEnterix (TRXC) Tops Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month high with Hormuz transits in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- Microsoft pulls out of UK data center deal with Nscale, Telegraph reports
- AST SpaceMobile partners with four European operators on MSS spectrum
- Lithuanians forced to take shelter after suspected drone enters airspace
TransEnterix, Inc. Reports Operating and Financial Results for the First Quarter 2020
May 14, 2020 6:55 AM EDTRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the first quarter of 2020.
Recent Highlights
Obtained FDA 510(k) clearance for First Machine Vision System in Robotic Surgery in March 2020 Received CE Mark approval for Pediatric indication for Senhance® Surgical System on February 12, 2020 Raised approximately $15 million in gross proceeds in an underwritten... More


